Drug Development · asia
InventisBio’s psoriasis drug meets phase 3 endpoints, with over 70% of patients achieving a 90% improvement in skin lesion scores
Oral TYK2 inhibitor nomelcitinib showed an efficacy signal in a 391-patient trial, but placebo response rates and detailed safety data have not yet been disclosed, and a direct comparison with an existing drug remains ongoing.
Whether an oral treatment can substantially improve the skin of patients with moderate-to-severe psoriasis is an important test in drug development. InventisBio announced on November 2 that the phase 3 trial of its nomelcitinib (D-2570) met its primary and key secondary endpoints: after 16 weeks of treatment, more than 70% of patients in each of the two treatment groups achieved PASI 90, meaning at least a 90% improvement from baseline in the Psoriasis Area and Severity Index.
The multicenter, randomized, double-blind trial enrolled 391 patients with moderate-to-severe plaque psoriasis, assigning them in a 1:1:1 ratio to two nomelcitinib treatment groups and a placebo group. According to the company’s press release, both treatment groups significantly outperformed placebo on the primary endpoint, with p<0.0001 for both statistical tests.
Results for near-clearance of skin lesions also met the prespecified threshold. The company’s formal announcement published in the Shanghai Securities News stated that more than 80% of patients in each treatment group met the key secondary endpoint: a Physician’s Global Assessment (PGA) score of 0 or 1, indicating completely or almost completely clear skin, together with an improvement of at least two points from baseline. Both measures showed significant differences from placebo starting at week 4.
Nomelcitinib is an oral selective TYK2 inhibitor. According to the company, it binds to the JH2 pseudokinase domain of TYK2 and inhibits downstream cytokine signaling associated with inflammation. This trial provides clinical evidence of improvement in skin symptoms, but PASI 90 does not mean the disease is cured, and the 16-week results alone cannot establish how long efficacy will last.
The information currently available remains a preliminary summary. Neither announcement provided exact placebo response rates or complete data and confidence intervals for each treatment group, making it difficult to assess the absolute benefit over placebo. The company said no new safety signals were identified but did not provide detailed adverse event rates; assessing the risks of long-term use still requires more complete data.
The next key question is how it performs against existing treatments. InventisBio said another phase 3 trial directly comparing nomelcitinib with deucravacitinib remains ongoing. The success of this placebo-controlled trial advances development, but it does not yet establish superiority over existing drugs. The company also cautioned in its formal announcement that these results would not have a material impact on its current financial performance.